UnknownNot Applicable

Gene Expression in Patients With Epiretinal Membranes

PolandStarted 2012-06

Plain-language summary

The purpose of this study was to investigate the expression of selected genes both in epiretinal membranes (ERMs) and peripheral blood mononuclear cells (PBMCs) from patients with primary and secondary epiretinal membranes in proliferative diabetic retinopathy. Possible correlations between messenger ribonucleic acid (mRNA) levels of these genes were also identified.

Who can participate

Age range

55 Years

Sex

ALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Caucasian race, * both males and females, * aged ≥ 55 years, * suffering from idiopathic ERMs or secondary ERMs in proliferative diabetic retinopathy (PDR). * Presence of ERM was proven in optical coherence tomography (OCT) examination. Exclusion criteria: * aged \< 55 years, * systemic connective tissue disease, * active inflammatory process

Questions worth asking your doctor

Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.

1Based on my diagnosis and history, is this trial worth exploring for me — or is there a standard treatment we should try first?
2What does this trial's phase tell us about how much is already known about its safety and benefit?
3What would taking part actually involve for me — visits, tests, time, and travel?
4What are the known and possible risks or side effects I should weigh, and how would they be monitored?
5If this trial isn't the right fit, what other options or trials would you suggest I look into?

Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.

Questions for the trial coordinator

The trial coordinator is the person who runs the study day to day. These cover the practical side — logistics, costs, and what taking part would actually mean for your life. The study team confirms whether you meet the criteria; these are questions to ask, not a sign you qualify.

1What does taking part actually involve week to week — how many visits, where, and how long does each one take?
2What costs are covered by the study, and what might I have to pay for myself, including travel, parking, or time off work?
3What happens during screening, and what happens if the study team confirms I don't meet the criteria after those tests?
4Who pays for the scans, blood work, and other tests the trial requires — the study, my insurance, or me?
5How will being in the trial affect my regular care, and will my own doctor stay informed and involved?
6Can I leave the trial at any point if I change my mind, and what would happen to my care if I do?

A starting point for the conversation — always confirm anything about your own eligibility, costs, and care with the study team and your doctor.

What they're measuring

Gene expression in patients with idiopathic and secondary epiretinal membranes in proliferative diabetic retinopathy.

Timeframe: The period between the diagnosis of the ERMs and the actual surgery for the condition was between 2 and 43 months.

Trial details

NCT IDNCT01946451

SponsorMedical University of Silesia

Sponsor typeOTHER

Study typeOBSERVATIONAL

Primary completion2013-09

View on ClinicalTrials.gov More Proliferative Diabetic Retinopathy trials